According to latest Wolters Kluwer Rx data released today Zubsolv w/w tablets market share were down 0.18 percentage points to 5.99%. However, the four week rolling average continues higher to new highs and the market share rose to 6.10%, up 0.02 percentage points from last week. Zubsolv TRx market share were also lower for the week by 0.06 percentage points, reaching a market share of 5.69%. The four week rolling average market share trend is positive and this rose to 5.65%. Monthly buprenorphine/naloxone unit sales shows a y/y growth rate of 8.9% and the monthly TRx shows a y/y growth rate of 6.9%.